PURPOSE: We report an observational study to evaluate the efficacy and tolerability of @entity4480 for @entity2335 . MATERIALS AND METHODS: A total of 48 @entity1 were prospectively treated for 2 months following an uptitration protocol to the target dose of 2 x 40 mg @entity4480 per day. @entity1 received the target dose for 5 weeks. The efficacy of @entity4480 treatment was assessed at week 8. The primary end point was a change in the overall well-being evaluated by a @entity1 reported global response assessment. Secondary end points were changes in @entity158 and urgency (visual analog scales), frequency and functional bladder capacity (48-hour voiding log), and changes in overall symptom severity (O'Leary-Sant index). RESULTS: There were 5 @entity1 (10.4%) who were identified as responders and 17 @entity1 (35.4%) who dropped out of the study exclusively due to side effects, with @entity390 present in all dropouts. No severe adverse events were reported. All 5 responders reported onset of symptom improvement but not until they had reached the target dose. Regarding secondary outcome parameters, @entity4480 treatment did not result in statistically significant improvement of symptoms. Maximum urinary flow rate and residual volume were influenced more prominently in @entity1 at the target dose, however, the changes did not appear to be clinically meaningful. CONCLUSIONS: Treatment of @entity2335 with @entity4480 did not result in significant improvement of symptoms. The drug administration was safe but the tolerability of the drug was poor mainly due to @entity390 occurring with the starting dose of 20 mg per day. Based on the preliminary data of this observational trial we currently cannot recommend @entity4480 as a therapeutic approach for @entity2335 .

The dual serotonin and noradrenaline reuptake inhibitor XXXX for the treatment of @entity2335 : results of an observational study.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity4480 :: ('MESH:C058218', 'Chemical') :: ['duloxetine'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity2335 :: ('MESH:D003556', 'Disease') :: ['interstitial cystitis']
@entity4480 :: (MESH:C058218,Chemical) :: ['duloxetine']
